For many families, hemangiosarcoma feels like a thief in the night.
A healthy, happy dog goes to bed… and the next day collapses without warning. Pale gums. Weakness. A swollen belly. An emergency rush to the vet. Within hours, pet parents hear a word they’ve never heard before: hemangiosarcoma.
This fast-growing cancer of the blood vessels is one of the most aggressive cancers in dogs. It often hides silently in the spleen or heart until a fragile tumor ruptures and causes sudden internal bleeding. By the time it’s found, it has usually already spread.
And historically, the outlook has been grim.
Even with surgery alone, survival is often just 1–3 months. Adding chemotherapy may extend that to 5–7 months, yet most dogs don’t survive a year. Nationwide, tens of thousands of dogs—especially breeds like Golden Retrievers, German Shepherds, Portuguese Water Dogs, and Labradors—are lost to this disease every year.
For decades, veterinarians treated hemangiosarcoma with the same tools: remove the tumor and use chemotherapy. But researchers didn’t fully understand why the cancer was so aggressive.
That’s now beginning to change.
Scientists at the University of Florida College of Veterinary Medicine recently identified a key genetic driver: a mutation in the PIK3CA gene. Think of this gene as a growth switch. When it mutates, it tells cancer cells to multiply faster, build new blood vessels, and even manipulate the immune system to protect the tumor. In other words, the cancer doesn’t just grow—it recruits the body to help it survive.
This discovery turns hemangiosarcoma from a “mystery cancer” into a targetable disease. Instead of only using broad chemotherapy, researchers can now design therapies aimed specifically at blocking this pathway.
Other labs are building on that momentum. At the University of Minnesota College of Veterinary Medicine, scientists are testing an engineered therapy called eBAT, which seeks out markers found almost exclusively on hemangiosarcoma cells and delivers a toxin directly to the tumor while sparing healthy tissue. Meanwhile, the Morris Animal Foundation is funding studies combining existing drugs like propranolol with chemotherapy to make cancer cells more sensitive to treatment, and institutions such as North Carolina State University are exploring infectious and inflammatory factors that may influence risk.
None of these is a cure yet, but together they represent something new: precision medicine.
For the first time, researchers aren’t just reacting to hemangiosarcoma. They’re uncovering its engine and learning how to shut it down. And that growing understanding is creating real hope that future dogs may face longer, healthier lives after diagnosis.